The following stocks are the leading risers and fallers on AIM on Tuesday.
----------
AIM - WINNERS
----------
MediaZest PLC, up 38% at 0.1 pence, 12-month range 0.055p-0.1p. The audio-visual solutions provider recounts a ‘solid’ second half of 2025 and says it expects annual revenue of around £4.0 million, up 30% from £3.1 million last year. It also expects to report ‘a modest profit after tax and a substantial [earnings before interest, tax, depreciation and amortisation] profit’, and for cash in hand to rise 50% to around £100,000 at the year’s end from £64,000. MediaZest also says it has successfully restructured its debt obligations following engagement with all its key debt holders, and that it has repaid in full an invoice discounting facility, as well as reaching a deal on existing loans and outstanding interest with shareholders and/or debt holders. Says this deal will write off £529,000 worth of interest and leave a principal sum of £785,609 to repay over the next six years, and that interest charges have ceased moving forwards.
----------
Kistos Holdings PLC, up 24% at 182.5 pence, 12-month range 103.5p-195p. The upstream and midstream-focused energy company says it has entered a binding agreement to acquire a 5% working interest in Block 9 and a 20% working interest in Blocks 3 & 4 from Mitsui E&P Middle East BV. Both are located in onshore Oman. Consideration totals $148 million, effective from January 1 and Kistos expects the deal to add 25.6 million barrels of oil equivalent of 2P reserves. Estimates additional production of approximately 9,000 to 10,000 boe per day net in 2025, and expects the acquisition to be immediately cash-generative. Says the acquisition equates to a valuation of approximately $5.80 per boe of 2P reserves. ‘Our entry into the MENA region represents an important step forward in our mission to build a resilient, future-facing energy company,’ comments Executive Chair Andrew Austin. ‘It not only complements our existing portfolio in the North Sea but also provides a platform for long-term growth and enhanced cash flow...this acquisition will increase our reserves to 50 mmboe and is expected to deliver a material uplift in Kistos’ production in 2026 to approximately 20,000 boepd.’
----------
AIM - LOSERS
----------
Renalytix PLC, down 7.4% at 6.25p, 12-month range 5.75p-12.5p. The precision medicine diagnostics company releases its annual general meeting statement from Executive Chair Julian Baines, who says the company continues to work towards wider adoption of the KidneyintelX.dkd test and that it has made good progress in increasing testing volumes across the four target states where it has a direct presence. ‘Whilst this is encouraging, our main growth strategy is to deliver significant testing volume ramp-up through business development initiatives with important strategic partnerships that can target adoption by larger health centres across the whole of the US. To this end, in mid-September we were delighted to secure a definitive agreement with NASDAQ listed Tempus AI Inc,’ he adds. Baines continues: ‘Engaging with large healthcare systems presents inherent challenges, particularly due to lengthy implementation and approval processes that are often outside of our direct control, but we are satisfied that with partnerships such as Tempus and MVP Health Care, this strategy will deliver long-term value for shareholders.’ Going forward, Baines says Renalytix is focused on converting ongoing business development activity into contracted relationships, expanded EHR integrations, and growing testing volumes. ‘While the timing of commercial outcomes - particularly with large healthcare systems-remains difficult to predict, the board and management are confident that the foundations being put in place today position the company well for sustainable revenue growth, increased operating leverage, and long-term value creation for shareholders,’ Baines says.
----------
Copyright 2025 Alliance News Ltd. All Rights Reserved.
